Intratumoral Cancer Therapies Global Market Report 2024

The intratumoral cancer therapies market size has grown rapidly in recent years. It will grow from $124.82 billion in 2023 to $141.55 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth observed in the historical period can be ascribed to advancements in cancer research, a rise in cancer incidence, the demand for precision medicine, clinical evidence and research initiatives, as well as unmet medical needs.

The intratumoral cancer therapies market size is expected to see rapid growth in the next few years. It will grow to $221.46 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The anticipated growth in the forecast period can be attributed to advancements in immunotherapy, a heightened adoption of precision medicine, the expansion of clinical trials, a growing focus on rare cancers, and regulatory support with subsequent approvals. Major trends expected in the forecast period include the exploration of intratumoral immunomodulators, the integration of image-guided therapies, the application of hyperthermia in intratumoral treatments, the initiation of clinical trials for combination therapies, and continued regulatory backing for intratumoral therapies.

The rising prevalence of cancer is anticipated to drive the expansion of the intratumoral cancer therapies market in the foreseeable future. Cancer comprises a group of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body. Intratumoral cancer therapies play a crucial role in the diagnosis and treatment of cancer by mitigating off-target toxicities, dose-limiting toxicities, and adverse effects resulting from immune stimulation in patients with cancer. For instance, as of January 2023, the American Cancer Society, a nonprofit cancer advocacy organization based in the United States, reported an increase in the number of cancer cases to 1,958,310, representing a growth of 3.16% from 1,898,160 in 2021. This, escalation in cancer incidence is a significant factor propelling the growth of the intratumoral cancer therapies market.

The integration of immunotherapy is expected to fuel the growth of the intratumoral cancer therapies market. Immunotherapy, a cancer treatment that enhances the body's immune system to identify and destroy cancer cells, is becoming increasingly prominent. Intratumoral therapies align with the growing emphasis on immunotherapy, providing a targeted and potent approach to modulating the immune response within the tumor microenvironment. Notably, in June 2022, the United States Food and Drug Administration (FDA) approved 35 ICI-based combination immunotherapies, highlighting the increasing integration of immunotherapy and its impact on the intratumoral cancer therapies market.

Technological advancements emerge as a noteworthy trend in the intratumoral cancer therapies market. Companies in this sector are adopting innovative technologies to maintain their market standing. For instance, in March 2022, Evonik, a US-based specialty chemical manufacturing company, introduced EUDRATEC SoluFlow, a novel microparticle technology designed to enhance the solubility of active medicinal components in oral cancer medication formulations. This breakthrough technology allows previously considered insoluble chemicals to be used in a broader range of oral medications.

In September 2022, CytoReason Ltd, an Israel-based biotechnology company, partnered with Pfizer Inc. to leverage artificial intelligence (AI) for drug discovery and development. Through this collaboration, Pfizer will incorporate CytoReason's AI technologies into its drug research activities, with the agreement valued up to $110 million over the next five years. Pfizer's contribution includes $20 million in stock, options to license CytoReason's platform and disease models, and additional project support. Pfizer Inc., a US-based pharmaceutical company specializing in intestine cancer therapeutics, aims to enhance its drug discovery efforts through this collaboration.

In January 2023, AstraZeneca, a UK-based biopharmaceutical firm focusing on oncology and rare diseases, acquired Neogene Therapeutics Inc. for $120 million. This acquisition expands AstraZeneca's capabilities in cancer treatment by incorporating Neogene Therapeutics Inc., an Amsterdam-based biotechnology research company offering personalized treatments based on TCR genes targeting neoantigens detected in a specific patient's tumor.

Major companies operating in the intratumoral cancer therapies market report are Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Celgene Corporation, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Aratana Therapeutics Inc., Regeneus Ltd., QBiotics Group, VetDC, AdvaVet Inc.

North America was the largest region in the intratumoral cancer therapies market in 2023. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intratumoral cancer therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of intratumoral cancer therapies encompass monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, and cytokines. Monoclonal antibodies denote a specific type of artificially created protein capable of binding to particular bodily targets, including antigens present on the surface of cancer cells. They find application in various contexts, such as lung cancer, breast cancer, melanoma, prostate cancer, head and neck cancer, among others, and are utilized by diverse end users, including hospitals, cancer research centers, and clinics.

The intratumoral cancer therapies market research report is one of a series of new reports that provides intratumoral cancer therapies market statistics, including intratumoral cancer therapies industry global market size, regional shares, competitors with an intratumoral cancer therapies market share, detailed intratumoral cancer therapies market segments, market trends and opportunities, and any further data you may need to thrive in the intratumoral cancer therapies industry. This intratumoral cancer therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.